NCT03534947 2025-12-16
SONIB
Melanoma Institute Australia
Phase 2 Completed
Clinical Trials
36 trialsNCT05188729 2025-06-18
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
Phase 2 Completed
NCT04552990 2025-04-23
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03132636 2025-04-08
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT04893486 2024-08-29
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Palvella Therapeutics, Inc.
Phase 2 Completed
NCT04669808 2024-03-18
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
Sirnaomics
Phase 2 Completed
NCT02667574 2022-10-17
VISMONEO
University Hospital, Lille
Phase 2 Completed
NCT05315128 2022-04-07
Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers
Zagazig University
Phase 2 Completed
NCT03035188 2022-02-11
NICCI
SRH Wald-Klinikum Gera GmbH
Phase 2 Completed
NCT03180528 2021-06-08
Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
Stanford University
Phase 2 Completed
NCT01556009 2020-11-02
Vismodegib
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT00489086 2020-10-29
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT03714529 2020-10-08
A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma
Herlev and Gentofte Hospital
Phase 2 Completed
NCT02354261 2020-08-05
Open-label Trial of SUBAâ„¢-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
HedgePath Pharmaceuticals, Inc.
Phase 2 Completed
NCT02762084 2020-07-23
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
PellePharm, Inc.
Phase 2 Completed
NCT01327053 2019-08-28
BOLT
Novartis
Phase 2 Completed
NCT01700049 2019-05-23
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Mayo Clinic
Phase 2 Completed
NCT02828111 2019-01-08
BCC
PellePharm, Inc.
Phase 2 Completed
NCT00021294 2018-09-11
Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis
University of Arizona
Phase 2 Completed
NCT01815840 2017-09-28
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
Hoffmann-La Roche
Phase 2 Completed
NCT00783965 2016-02-11
Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT00089180 2015-12-04
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
National Cancer Institute (NCI)
Phase 2 Completed
NCT00961896 2015-11-03
A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients
Novartis
Phase 2 Completed
NCT01350115 2015-10-19
Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)
Novartis
Phase 2 Completed
NCT00833417 2015-05-20
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00108121 2015-01-19
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
Peplin
Phase 2 Completed
NCT01358045 2015-01-13
Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma
Maastricht University Medical Center
Phase 2 Completed
NCT00959647 2015-01-07
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT01543581 2014-09-26
Erivedge
Loma Linda University
Phase 2 Completed
NCT01201915 2014-06-24
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00002975 2013-10-10
Photodynamic Therapy in Treating Patients With Skin Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00023621 2013-06-26
Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002963 2013-01-31
Photodynamic Therapy in Treating Patients With Skin Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00586040 2009-04-10
PTB
Massachusetts General Hospital
Phase 2 Completed
NCT00108134 2008-12-24
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell Carcinoma
Peplin
Phase 2 Completed
NCT00188370 2005-09-16
Ultrasound Biomicroscopy - Apoptosis
University Health Network, Toronto
Phase 2 Completed